Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 111,049 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 111,049 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $71.46, for a total value of $7,935,561.54. Following the transaction, the director owned 1,065,135 shares in the company, valued at approximately $76,114,547.10. This trade represents a 9.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Liquidia Price Performance

Shares of LQDA opened at $68.01 on Wednesday. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $73.22. The stock has a market cap of $6.05 billion, a P/E ratio of 485.82 and a beta of 0.58. The stock’s 50-day moving average price is $51.14 and its two-hundred day moving average price is $41.50.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm had revenue of $132.87 million for the quarter, compared to analysts’ expectations of $119.44 million. The company’s revenue for the quarter was up 4187.1% on a year-over-year basis. On average, equities analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Several institutional investors have recently modified their holdings of the business. Apis Capital Advisors LLC acquired a new stake in Liquidia in the 3rd quarter valued at approximately $9,569,000. Farallon Capital Management LLC raised its position in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after buying an additional 4,326,876 shares during the last quarter. GSA Capital Partners LLP raised its position in Liquidia by 63.6% in the 4th quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock valued at $2,179,000 after buying an additional 24,555 shares during the last quarter. Tudor Investment Corp ET AL acquired a new stake in Liquidia in the 3rd quarter valued at approximately $1,536,000. Finally, State of New Jersey Common Pension Fund D acquired a new stake in Liquidia in the 4th quarter valued at approximately $709,000. Institutional investors own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LQDA. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Needham & Company LLC raised their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Wall Street Zen upgraded Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. HC Wainwright lifted their price objective on Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a report on Friday, June 5th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $60.29.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).